Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07076862 · ClinicalTrials.gov registry record · Early Phase 1
Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)
A Early Phase 1 study of PASC Post Acute Sequelae of COVID 19, sponsored by University of California, Davis.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 51
- Enrollment target
- 2
- Study locations
NCT07076862 is a Early Phase 1 study of PASC Post Acute Sequelae of COVID 19 that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 51 participants, below the 224-participant average among 6 other PASC Post Acute Sequelae of COVID 19 trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT07076862, a Early Phase 1 study of PASC Post Acute Sequelae of COVID 19, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 51 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study uses total-body \[¹⁸F\]F-AraG PET/CT imaging to investigate immune activation and vascular changes in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Participants will undergo dynamic PET/CT imaging along with blood biomarker assessments and symptom evaluations. The study aims to characterize sites of immunological perturbation, correlate PET imaging findings with peripheral blood markers, and evaluate longitudinal changes in tissue-based immune activity in relation to symptom patterns over time. Data from this study will improve understanding of tissue-level immune dysregulation in PASC and support future clinical tools for assessing and managing this condition.
Conditions Studied
Interventions
- DRUG A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)
- DRUG A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)
- DRUG B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)
- DRUG B.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)
Study Locations (2)
California
- UC Davis EXPLORER Molecular Imaging Center - Sacramento
- University of California San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2025-12-04 |
| Est. Completion | 2029-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07076862
The ClinicalTrials.gov registry entry for NCT07076862 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 224-participant average among 6 other PASC Post Acute Sequelae of COVID 19 trials with a reported enrollment target (77% lower). The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with PASC Post Acute Sequelae of COVID 19 appearing as the primary indexed condition, and to 4 interventions - of which A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static) is the first listed.
NCT07076862 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07076862 about?
NCT07076862 is a clinical study titled "Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)". This study uses total-body \[¹⁸F\]F-AraG PET/CT imaging to investigate immune activation and vascular changes in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Participants will undergo dynamic PET/CT imaging along with blood biomarker assessments and ...
What is the current status of trial NCT07076862?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 51 participants. The study started on 2025-12-04. Estimated completion is 2029-12.
What conditions does trial NCT07076862 study?
This clinical trial studies the following conditions: PASC Post Acute Sequelae of COVID 19.
What interventions are being tested in trial NCT07076862?
The interventions under investigation include: A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static) (DRUG), A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only) (DRUG), B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static) (DRUG), B.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only) (DRUG).
Who is sponsoring clinical trial NCT07076862?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07076862 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PASC Post Acute Sequelae of COVID 19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation
RECRUITING · Phase 2
-
Neural Mechanisms of Fatigue in Post-Acute Sequela of SARS-CoV-2
RECRUITING · NA
-
Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection
RECRUITING
-
Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
ACTIVE NOT RECRUITING
-
A Pilot rTMS Trial for Neuropsychiatric Symptoms of Long-COVID
ACTIVE NOT RECRUITING · NA
-
Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.